New data has demonstrated that DNA fragment size differences that discriminate preeclampsia from healthy controls can be detected using a lower-cost PCR method.
Company researchers have shown that EpiDirect can detect and quantify 5mC without bisulfite treatment, demonstrating it on a promoter in human brain tumor samples.
Adela Closes $48M Financing to Develop Cancer Monitoring, Early Detection Test
The company will use the proceeds to advance its technology platform and commercialize its first product for minimal residual disease monitoring.
Rare Kidney Cancer Genomic Analysis Reveals Potential Target, Suggests Treatment
Investigators from the UK analyzed samples from two reninoma patients by whole-genome and RNA sequencing and found rearrangements of the NOTCH1 gene.
Invitae Publishes First Validation Data on MRD Assays, Laying Path to Future Clinical Expansion
Premium
The analytical validity study is the first published featuring full performance data for the firm's Personalized Cancer Monitoring technology.